Circulating miRNAs signature on breast cancer: the MCC-Spain project.

Nov 06, 2023

Experts: Inés Gómez-Acebo,Javier Llorca,Jessica Alonso-Molero,Marta Díaz-Martínez,Beatriz Pérez-Gómez,Pilar Amiano,Thalía Belmonte,Antonio J Molina,Rosana Burgui,Gemma Castaño-Vinyals,Víctor Moreno,Ana Molina-Barceló,Rafael Marcos-Gragera,Manolis Kogevinas,Marina Pollán,Trinidad Dierssen-Sotos

To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer.
miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization.
The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82.
We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported.

© 2023. The Author(s).

Author

admin

View all posts

ABOUT THE EXPERTS

Inés Gómez-Acebo,Javier Llorca,Jessica Alonso-Molero,Marta Díaz-Martínez,Beatriz Pérez-Gómez,Pilar Amiano,Thalía Belmonte,Antonio J Molina,Rosana Burgui,Gemma Castaño-Vinyals,Víctor Moreno,Ana Molina-Barceló,Rafael Marcos-Gragera,Manolis Kogevinas,Marina Pollán,Trinidad Dierssen-Sotos

Inés Gómez-Acebo

Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain. ines.gomez@unican.es.

IDIVAL, Santander, Spain. ines.gomez@unican.es.

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain. ines.gomez@unican.es.

Javier Llorca

Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Jessica Alonso-Molero

Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.

IDIVAL, Santander, Spain.

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Marta Díaz-Martínez

Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.

Beatriz Pérez-Gómez

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

Pilar Amiano

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, San Sebastian, Spain.

Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain.

Thalía Belmonte

IUOPA, University of Oviedo and ISPA (Health Research Institute of Asturias), Oviedo, Spain.

Antonio J Molina

Grupo de Investigación en Interacción, Gen-Ambiente-Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain.

Rosana Burgui

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Institute of Public and Occupational Health of Navarre (ISPLN), 31003, Pamplona, Spain.

Gemma Castaño-Vinyals

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.

Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Víctor Moreno

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Colorectal Cancer Group, ONCOBELL Program, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.

Oncology Data Analytics Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.

Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain.

Ana Molina-Barceló

Cancer and Public Health UnitFoundation for the Promotion of Health and Biomedical Research (FISABIO-Salud Pública) in the Valencia Region, Valencia, Spain.

Rafael Marcos-Gragera

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi), Girona, Spain.

Manolis Kogevinas

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.

Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Marina Pollán

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.

National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.

Trinidad Dierssen-Sotos

Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.

IDIVAL, Santander, Spain.

Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.